Metabolic dysfunction‐associated steatotic liver disease (SLD) and alcohol‐associated liver disease, but not SLD without metabolic dysfunction, are independently associated with new onset of chronic kidney disease during a 10‐year follow‐up period Kazuma Mori, Marenao Tanaka, Tatsuya Sato, Yukinori Akiyama, Keisuke Endo, Toshifumi Ogawa, Toru Suzuki, Hiroki Aida, Wataru Kawaharata, Kei Nakata, Itaru Hosaka, Araya Umetsu, Nagisa Hanawa, Masato Furuhashi Hepatology Research.2025; 55(1): 34. CrossRef
Metabolic dysfunction-associated steatotic liver disease and risk of four intrahepatic and extrahepatic diseases Yiyuan Xiao, Sihua Xu, Wenyan Hu, Jiapeng Huang, Deke Jiang, Rong Na, Zhaoqing Yin, Jingjing Zhang, Haitao Chen Annals of Hepatology.2025; 30(1): 101750. CrossRef
Chronic Kidney Disease Risk Associated With Metabolic Dysfunction‐Associated Steatotic Liver Disease: A Nationwide Cohort Study in Korea Dong Wook Kim, Minkook Son, Hye Jung Lee, Chi Hyeon Choi, Yeo Wool Kang, Sang Yi Moon, Myeongseok Koh, Jong Yoon Lee, Yang Hyun Baek, Won Suk An Hepatology Research.2025; 55(9): 1239. CrossRef
Changes in the epidemiological trends of primary liver cancer in the Asia–Pacific region Pojsakorn Danpanichkul, Kanokphong Suparan, Banthoon Sukphutanan, Chuthathip Kaeosri, Primrose Tothanarungroj, Supapitch Sirimangklanurak, Markos Kalligeros, Natchaya Polpichai, Yanfang Pang, Karn Wijarnpreecha, Pimsiri Sripongpun, Naichaya Chamroonkul, M Scientific Reports.2024;[Epub] CrossRef
Pemafibrate Reduced Liver Stiffness in Patients with Metabolic Dysfunction-associated Steatotic Liver Disease Complicated with Hyperlipidemia and Liver Fibrosis with a Fibrosis-4 Index Above 1.3 Tatsuki Ichikawa, Mio Yamashima, Shinobu Yamamichi, Makiko Koike, Yusuke Nakano, Hiroyuki Yajima, Osamu Miyazaki, Tomonari Ikeda, Takuma Okamura, Naohiro Komatsu, Sayuri Sugio, Miruki Yoshino, Hisamitsu Miyaaki Internal Medicine.2024;[Epub] CrossRef
Assessing Nutritional Factors for Metabolic Dysfunction-Associated Steatotic Liver Disease via Diverse Statistical Tools Yea-Chan Lee, Hye Sun Lee, Soyoung Jeon, Yae-Ji Lee, Yu-Jin Kwon, Ji-Won Lee Diabetes & Metabolism Journal.2026; 50(1): 178. CrossRef
Reduced skeletal muscle mass and elevated phase angle are linked to metabolic dysfunction-associated steatotic liver disease in Japanese males Satoko Tajirika, Takao Miwa, Masahito Shimizu, Mayumi Yamamoto Nutrition.2026; : 113118. CrossRef
Metabolic dysfunction-associated steatotic liver disease and risk of four intrahepatic and extrahepatic diseases Yiyuan Xiao, Sihua Xu, Wenyan Hu, Jiapeng Huang, Deke Jiang, Rong Na, Zhaoqing Yin, Jingjing Zhang, Haitao Chen Annals of Hepatology.2025; 30(1): 101750. CrossRef
Role of noninvasive tests in the prognostication of metabolic dysfunction-associated steatotic liver disease Yue Wang, Sherlot Juan Song, Yichong Jiang, Jimmy Che-To Lai, Grace Lai-Hung Wong, Vincent Wai-Sun Wong, Terry Cheuk-Fung Yip Clinical and Molecular Hepatology.2025; 31(Suppl): S51. CrossRef
C-C motif chemokines ligand 7 contributes to metabolic dysfunction-associated steatotic liver disease by enabling redox-sensitive induction of hypermethylated in cancer 1 Xinyue Sun, Jinge Wu, Huiqian Lv, Ben Wang, Xuelian Chen, Wenjing Ren, Xiulian Miao, Yan Guo, Xiaocen Kong, Huihui Xu, Zeqing Bao, Yong Xu, Zilong Li Metabolism.2025; 168: 156242. CrossRef
Pemafibrate Reduced Liver Stiffness in Patients with Metabolic Dysfunction-associated Steatotic Liver Disease Complicated with Hyperlipidemia and Liver Fibrosis with a Fibrosis-4 Index Above 1.3 Tatsuki Ichikawa, Mio Yamashima, Shinobu Yamamichi, Makiko Koike, Yusuke Nakano, Hiroyuki Yajima, Osamu Miyazaki, Tomonari Ikeda, Takuma Okamura, Naohiro Komatsu, Sayuri Sugio, Miruki Yoshino, Hisamitsu Miyaaki Internal Medicine.2025; 64(9): 1296. CrossRef
All-cause and disease-specific mortality in young adults with MASLD: A nationwide cohort study Jeayeon Park, Goh Eun Chung, Su Jong Yu, Yoon Jun Kim, Jung-Hwan Yoon, Kyungdo Han, Eun Ju Cho JHEP Reports.2025; 7(9): 101477. CrossRef
Evolving Public Attention to Steatotic Liver Disease: A 20‐Year Analysis (2004–2024) Pojsakorn Danpanichkul, Charat Thongprayoon, Kanokphong Suparan, Donghee Kim, Ornpailin Wanichthanaolan, Phuuwadith Wattanachayakul, Yanfang Pang, Mark D. Muthiah, Anand V. Kulkarni, Ju Dong Yang, Apichat Kaewdech, Wisit Cheungpasitporn, Karn Wijarnpreech Journal of Gastroenterology and Hepatology.2025; 40(8): 2053. CrossRef
Impact of Continuous Nutritional Counseling on Liver Function and Body Composition in Patients with MASLD/MASH Shiho Asai, Naoto Kawabe, Akemi Ito, Teiji Kuzuya, Eizaburo Ohno, Takuji Nakano, Kazunori Nakaoka, Hiroyuki Tanaka, Yuka Ochi, Sayuri Miyaji, Sayaka Morisaki, Yoshiki Hirooka Kanzo.2025; 66(6): 222. CrossRef
Temporal Trends in Cardiovascular Mortality in Underlying Viral Hepatitis: A Retrospective Analysis of Gender, Racial/Ethnic, and Regional Disparities Wania Sultan, Haider Ashfaq, Hamza Ashraf, Ahmad Khan, Ayman Omair Hashmi, Muhammad Omar Larik, Maheen Zahid, Yasir Majeed, Pratik Bhattarai, Ashujot K. Dang, Ahmed Ali Aziz, Hafiz Muhammad Sharjeel Arshad JGH Open.2025;[Epub] CrossRef
Phocaeicola dorei
ameliorates progression of steatotic liver disease by regulating bile acid, lipid, inflammation and proliferation
Jieun Choi, Ye Rin Choi, Min Kyo Jeong, Hyun Ho Song, Jeong Seok Yu, Seol Hui Song, Jeong Ha Park, Min Ju Kim, Hyunjoon Park, Young Lim Ham, Sang Hak Han, Dong Joon Kim, Do Yup Lee, Ki Tae Suk Gut Microbes.2025;[Epub] CrossRef
Usefulness of health checkup‐based indices in identifying metabolic dysfunction‐associated steatotic liver disease Takao Miwa, Satoko Tajirika, Nanako Imamura, Miho Adachi, Ryo Horita, Tatsunori Hanai, Cheng Han Ng, Mohammad Shadab Siddiqui, Taku Fukao, Masahito Shimizu, Mayumi Yamamoto JGH Open.2024;[Epub] CrossRef
Association between nonalcholic fatty liver disease and pancreatic cancer: Epidemiology, mechanisms, and antidiabetic medication Takahiko Sakaue, Hiroya Terabe, Hidetoshi Takedatsu, Takumi Kawaguchi Hepatology Research.2024; 54(8): 729. CrossRef
Equivalent prevalence and progression of chronic kidney disease in non-alcoholic fatty liver disease and metabolic dysfunction-associated steatotic liver disease Hiroyuki Suzuki, Tsubasa Tsutsumi, Machiko Kawaguchi, Keisuke Amano, Takumi Kawaguchi Clinical and Molecular Hepatology.2024; 30(4): 962. CrossRef
Role of noninvasive tests in the prognostication of metabolic dysfunction-associated steatotic liver disease Yue Wang, Sherlot Juan Song, Yichong Jiang, Jimmy Che-To Lai, Grace Lai-Hung Wong, Vincent Wai-Sun Wong, Terry Cheuk-Fung Yip Clinical and Molecular Hepatology.2025; 31(Suppl): S51. CrossRef
Is type 2 diabetes a link between lung function and metabolic dysfunction–associated steatotic liver disease? Insights from population studies and Mendelian randomization Runmin Cao, Yurun Zhang, Ling Cao, Honghe Jiang European Journal of Gastroenterology & Hepatology.2025; 37(5): 652. CrossRef
In-silico identification and experimental validation of shared genes and pathways to decipher the molecular links between COPD and MASLD Anupama Dubey, Praveen Kumar, Tahseen Khan, Suneel Kateriya, Dinesh Mani Tripathi, Umesh C.S. Yadav Computers in Biology and Medicine.2025; 194: 110532. CrossRef
Increased risk of acute exacerbation in obstructive airway disease: the impact of metabolic dysfunction-associated steatotic liver disease and small airway dysfunction Che-Hao Tseng, Bor-Yang Jou, Hsiao-Chin Shen, Hsiao-Yun Yeh, Shiao-Ya Hong, Yi-Hsuan Lin, Hung-Cheng Tsai, Tzu-Hao Li, Chien-Wei Su, Kun-Ta Chou, Diahn Warng Perng, Ying-Ying Yang, Ming-Chih Hou BMJ Open Respiratory Research.2025; 12(1): e003352. CrossRef
Association of hepatic steatosis and liver fibrosis with chronic obstructive pulmonary disease among adults Dayang Zheng, Xiang Liu, Wei Zeng, Wangyan Zhou, Chunxiang Zhou Scientific Reports.2024;[Epub] CrossRef
Clinical Profile of Psoriasis Patients With Comorbid Fatty Liver and Risk Factors for Advanced Liver Fibrosis in Those With Metabolic Dysfunction–Associated Steatotic Liver Disease Hidenori Watabe, Tomomitsu Miyagaki, Kaori Nakajima, Ken Go, Tatsuro Okano, Takafumi Kadono The Journal of Dermatology.2026; 53(2): 237. CrossRef
Hepatic Safety of IL-17 Inhibitors in Psoriasis and Psoriatic Arthritis: A 12-Month Retrospective Cohort Evaluation Using the FIB-4 Index Umut Bakay, Tugba Izci Duran, Ozge Sevil Karstarli Bakay, Rahime Ekmekcioglu Dermatology Practical & Conceptual.2026; 16(1): 6746. CrossRef
Effects of Biologics on Fibrosis-4 Index in Patients with Psoriasis Takashi Morita, Susumu Ichiyama, Michiko Ito, Saeko Ozaki, Taeang Arai, Masanori Atsukawa, Katsuhiko Iwakiri, Teppei Hagino, Toshihiko Hoashi, Naoko Kanda, Hidehisa Saeki Journal of Nippon Medical School.2025; 92(1): 88. CrossRef
Effects of Guselkumab on the FIB‐4 Index in Psoriasis Patients (EGIPT): A Three‐Year Study Edoardo Mortato, Lorenzo Marcelli, Lorenzo Tofani, Alfredo Belcastro, Marina Talamonti, Claudia Paganini, Cosimo Di Raimondo, Luca Bianchi, Marco Galluzzo The Journal of Dermatology.2025; 52(6): 1113. CrossRef
MASLD and liver fibrosis in patients with psoriasis receiving IL-17 or IL-23 inhibitors: a systematic review José González Fernández, Lucía Prieto-Torres, Mariano Ara Martín, Samuel J. Martínez-Domínguez Therapeutic Advances in Gastroenterology.2025;[Epub] CrossRef
Hub Genes Involved in the Progression of Nonalcoholic Fatty Liver Disease to Hepatocellular Carcinoma Baiyi Liu, Xiaoxiao Wang, Nan Wu, Feng Liu, Huiying Rao Current Medicinal Chemistry.2025; 32(23): 4786. CrossRef
The Intriguing Roles of Cytokines in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Narrative Review Ilias D. Vachliotis, Stergios A. Polyzos Current Obesity Reports.2025;[Epub] CrossRef
Relación entre el control de la psoriasis y la enfermedad hepática esteatósica asociada a disfunción metabólica Citlalli Guadalupe Hernández Guzmán, Blanca Elena Verazaluce Rodríguez, Lauro Fabián Amador Medina, Graciela López Mata, Erick Josefat Díaz Huerta, Óscar Noel Chávez Hernández Piel.2025; 40(9): 558. CrossRef
Biologic Therapy and Malignancy Risk in Psoriasis: A Retrospective Cohort Study Saori Takamura, Souichiro Saito, Sora Sugai, Yuki Shiko, Takumi Yamaguchi, Yohei Kawasaki, Tomoo Fukuda The Journal of Dermatology.2025; 52(12): 1796. CrossRef
FIB-4 as an effective screening tool in psoriatic arthritis patients at high-risk for liver disease: a cross-sectional study using FibroScan Katya Meridor, Stephanie R Harrison, Richard Parker, Chenchu Chimakurthi, Philip M Laws, Dennis McGonagle, Andrew Barr, Claire Y Vandevelde, Helena Marzo-Ortega, Jane E Freeston Rheumatology.2025;[Epub] CrossRef
Bimekizumab safety in moderate to severe plaque psoriasis: Rates of hepatic events and changes in liver parameters over 2 years in randomized phase 3/3b trials Mark Lebwohl, Joseph F. Merola, Bruce Strober, April Armstrong, Ayumi Yoshizaki, Paolo Gisondi, Balint Szilagyi, Luke Peterson, Dirk de Cuyper, Nancy Cross, Owen Davies, Alice B. Gottlieb Journal of the American Academy of Dermatology.2024; 91(2): 281. CrossRef
Interleukin‐23 inhibitors decrease Fibrosis‐4 index in psoriasis patients with elevated Fibrosis‐4 index but not interleukin‐17 inhibitors Ryosuke Takeshima, Masahiro Kamata, Shoya Suzuki, Makoto Ito, Ayu Watanabe, Hideaki Uchida, Chika Chijiwa, Yoshiki Okada, Saori Azuma, Mayumi Nagata, Shota Egawa, Azusa Hiura, Saki Fukaya, Kotaro Hayashi, Atsuko Fukuyasu, Takamitsu Tanaka, Takeko Ishikawa The Journal of Dermatology.2024; 51(9): 1216. CrossRef
Immune system dysregulation in the pathogenesis of non-alcoholic steatohepatitis: unveiling the critical role of T and B lymphocytes Merve Cebi, Yusuf Yilmaz Frontiers in Immunology.2024;[Epub] CrossRef
Evolution of FIB-4 score in SpA and PsA patients taking anti-TNF or anti-IL17 Frank Verhoeven, Clément Prati, Vincent Di Martino, Thierry Thevenot, Céline Demougeot, Daniel Wendling, Delphine Weil-Verhoeven Joint Bone Spine.2024; 91(6): 105763. CrossRef
Application of graph theory in liver research: A review Xumei Hu, Longyu Sun, Rencheng Zheng, Xueqin Xia, Meng Liu, Weibo Chen, Xinyu Zhang, Chengyan Wang Portal Hypertension & Cirrhosis.2024; 3(4): 234. CrossRef
Real-World Screening Data for Liver Fibrosis in Psoriasis Patients Treated with Biologics Susumu Ichiyama, Michiko Ito, Saeko Ozaki, Taeang Arai, Masanori Atsukawa, Katsuhiko Iwakiri, Teppei Hagino, Toshihiko Hoashi, Naoko Kanda, Hidehisa Saeki Journal of Nippon Medical School.2024; 91(6): 534. CrossRef
The beneficial impact of metabolic dysfunction‐associated fatty liver disease on lenvatinib treatment in patients with non‐viral hepatocellular carcinoma Shigeo Shimose, Atsushi Hiraoka, Andrea Casadei‐Gardini, Tsubasa Tsutsumi, Dan Nakano, Hideki Iwamoto, Fujimasa Tada, Margherita Rimini, Masatoshi Tanaka, Takuji Torimura, Hideya Suga, Hideko Ohama, Valentina Burgio, Takashi Niizeki, Etsuko Moriyama, Hiro Hepatology Research.2023; 53(2): 104. CrossRef
The Inter-Organ Crosstalk Reveals an Inevitable Link between MAFLD and Extrahepatic Diseases Tsubasa Tsutsumi, Dan Nakano, Ryuki Hashida, Tomoya Sano, Machiko Kawaguchi, Keisuke Amano, Takumi Kawaguchi Nutrients.2023; 15(5): 1123. CrossRef
Mechanism-based target therapy in primary biliary cholangitis: opportunities before liver cirrhosis? Yushu Yang, XiaoSong He, Manuel Rojas, Patrick S. C. Leung, Lixia Gao Frontiers in Immunology.2023;[Epub] CrossRef
Ultrasonographic Assessment of Tissue Stiffness: Recent Progress in Transient Elastography and Shear Wave Elastography in the Liver and Various Organs MASAHITO NAKANO, RYOKO KUROMATSU, TAKUMI KAWAGUCHI The Kurume Medical Journal.2023; 70(1.2): 1. CrossRef
Gut dysbiosis in nonalcoholic fatty liver disease: pathogenesis, diagnosis, and therapeutic implications Jie Fang, Chen-Huan Yu, Xue-Jian Li, Jin-Mei Yao, Zheng-Yu Fang, Soo-Hyun Yoon, Wen-Ying Yu Frontiers in Cellular and Infection Microbiology.2022;[Epub] CrossRef
Liver fibrosis prevalence and risk factors in patients with psoriasis: A systematic review and meta-analysis Tanat Yongpisarn, Amornrut Namasondhi, Wimolsiri Iamsumang, Ploysyne Rattanakaemakorn, Poonkiat Suchonwanit Frontiers in Medicine.2022;[Epub] CrossRef
First
Prev
